Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Ischemia Reperfusion Induced Endothelial Dysfunction
NCT05217654Phase 1Unknown
- Sponsor
- Medical University of Vienna
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in reperfusion injury (IRI) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Acetylcholine - Area under the curve forearm blood flow measurement at 14 days. Status: unknown.
02
Drugs
dapagliflozin
03
Conditions
reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT05217654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217654.